MorphoSys (MOR) Given a €93.00 Price Target by Oddo Bhf Analysts
MorphoSys (ETR:MOR) has been given a €93.00 ($114.81) price objective by analysts at Oddo Bhf in a report issued on Wednesday. The brokerage currently has a “buy” rating on the stock. Oddo Bhf’s price target would suggest a potential upside of 8.20% from the stock’s previous close.
MOR has been the subject of several other research reports. JPMorgan Chase & Co. set a €86.00 ($106.17) price objective on MorphoSys and gave the company a “buy” rating in a research note on Tuesday, December 12th. Goldman Sachs Group set a €80.00 ($98.77) price objective on MorphoSys and gave the company a “neutral” rating in a research note on Monday, November 27th. Royal Bank of Canada set a €57.00 ($70.37) price objective on MorphoSys and gave the company a “sell” rating in a research note on Wednesday, February 14th. Independent Research set a €93.00 ($114.81) price objective on MorphoSys and gave the company a “buy” rating in a research note on Friday, December 1st. Finally, Berenberg Bank set a €85.00 ($104.94) price objective on MorphoSys and gave the company a “buy” rating in a research note on Thursday, December 7th. Two research analysts have rated the stock with a sell rating, two have given a hold rating and seven have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus target price of €84.02 ($103.73).
Shares of MorphoSys (ETR:MOR) traded down €1.30 ($1.60) on Wednesday, hitting €85.95 ($106.11). The stock had a trading volume of 180,040 shares, compared to its average volume of 151,566. The stock has a market cap of $2,530.00 and a PE ratio of -35.66. MorphoSys has a fifty-two week low of €49.63 ($61.27) and a fifty-two week high of €88.40 ($109.14).
MorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnerships with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation.
Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter.